HealOr names Dr Michael Sabolinski CEO
This article was originally published in Scrip
HealOr, a speciality biopharmaceutical company developing topical therapeutics for treating chronic wounds such as diabetic foot ulcer, has named Dr Michael Sabolinski chief executive officer. Dr Sabolinski has 25 year's experience in wound-care research, and was previously HealOr's chief medical officer. Prior to HealOr, he served as Organogenesis' president and CEO.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.